Illustration: Aïda Amer/Axios
This week has seen nearly $15 billion in biotech M&A, and one acquisition candidate, lauded at ASCO last month, is still sitting on the sidelines.
Zoom in: Revolution Medicine's recent data readouts in pancreatic cancer could reignite takeover interest in the clinical-stage company.
